Digitalni repozitorij raziskovalnih organizacij Slovenije

Iskanje po repozitoriju
A+ | A- | Pomoč | SLO | ENG

Iskalni niz: išči po
išči po
išči po
išči po

Možnosti:
  Ponastavi


Iskalni niz: "avtor" (Samo Rožman) .

1 - 10 / 13
Na začetekNa prejšnjo stran12Na naslednjo stranNa konec
1.
Treatment outcomes and relative dose intensity of chemotherapy in patients with advanced Hodgkin lymphoma
Samo Rožman, Barbara Jezeršek Novaković, Nina Ružić Gorenjec, Srdjan Novaković, 2022, izvirni znanstveni članek

Povzetek: The present retrospective study was undertaken to investigate the association of relative dose intensity (RDI) with the outcome of patients with advanced stage Hodgkin lymphoma (HL) receiving ABVD (doxorubicin, bleomycin, vinblastine, dacarbazine) and escalated BEACOPP regimens (bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine, prednisone). A total of 114 patients with HL treated between 2004 and 2013 were enrolled for evaluation. The association of variables with overall survival (OS) and progression-free survival (PFS) was analysed using univariate and multivariate Cox proportional hazards models. The median age of patients was 39 years, and the majority were male and had stage IV disease. A total of 54 patients received ABVD and 60 received BEACOPP chemotherapy with 24 and four deaths, respectively. Patients in the BEACOPP group were significantly younger with lower Charlson comorbidity index (CCI) and better performance status in comparison with the ABVD group, making the comparison of groups not possible. In the ABVD group, RDI was not significantly associated with OS (P=0.590) or PFS (P=0.354) in a multivariate model where age was controlled. The low number of events prevented this analysis in the BEACOPP group. The age of patients was strongly associated with both OS and PFS; all statistically significant predictors for OS and PFS from univariate analyses (chemotherapy regimen, CCI, RDI, performance status) lost their effect in multivariate analyses where age was controlled. Based on these observations, it was concluded that RDI was not associated with OS or PFS after age is controlled, neither in all patients combined nor in the ABVD group.
Ključne besede: Hodgkin lymphoma, chemotherapy, outcome, primary treatment
Objavljeno v DiRROS: 23.09.2022; Ogledov: 150; Prenosov: 46
.pdf Celotno besedilo (794,55 KB)

2.
3.
4.
5.
Pogled kliničnega farmacevta
Samo Rožman, 2020, samostojni strokovni sestavek ali poglavje v monografski publikaciji

Ključne besede: farmacija, nefrologija, protitrombotično zdravljenje
Objavljeno v DiRROS: 06.04.2021; Ogledov: 941; Prenosov: 225
.pdf Celotno besedilo (50,35 KB)

6.
7.
8.
Razvojni trendi v onkološki farmaciji
Samo Rožman, 2016, objavljeni strokovni prispevek na konferenci

Ključne besede: onkologija, sistemsko zdravljenje, solidni tumorji, imunoterapija
Objavljeno v DiRROS: 16.09.2019; Ogledov: 1570; Prenosov: 485
.pdf Celotno besedilo (352,55 KB)

9.
Napotki za premagovanje neželenih učinkov sistemskega zdravljenja raka : kaj morate vedeti?
Simona Borštnar, Boštjan Šeruga, Marjana Bernot, Marika Horvat, Barbara Jezeršek Novaković, Denis Mlakar-Mastnak, Janja Ocvirk, Samo Rožman, Monika Sonc, Snežana Umičević, Metka Zajc, Branko Zakotnik, 2018, slovar, enciklopedija, leksikon, priročnik, atlas, zemljevid

Povzetek: V knjižici opisujemo različne vrste sistemskega zdravljenja, kamor uvrščamo zdravljenje s citostatiki (to je s kemoterapijo), hormonskimi zdravili in tarčnimi zdravili. S temi zdravili pa ne vplivamo samo na rakave celice, ampak tudi na zdrave celice v telesu, zaradi česar med zdravljenjem lahko nastanejo neželeni učinki. Nekatere neželene učinke lahko preprečimo ali pa jih uspešno lajšamo, če se že pojavijo.
Ključne besede: onkologija, bolniki, nasveti
Objavljeno v DiRROS: 25.03.2019; Ogledov: 2437; Prenosov: 713
.pdf Celotno besedilo (739,11 KB)

10.
Hipotiroza in spremenjena biološka razpoložljivost levotiroksina : primer bolnice
Olivera Pečanac, Samo Rožman, 2010, strokovni članek

Objavljeno v DiRROS: 31.08.2018; Ogledov: 2117; Prenosov: 572
.pdf Celotno besedilo (140,22 KB)

Iskanje izvedeno v 0.56 sek.
Na vrh